Valaciclovir detailed information

Jump to navigation Jump to search
Valaciclovir detailed information
File:Valaciclovir.svg
Clinical data
Pregnancy
category
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • S4 (Au), POM (UK), ℞-only (U.S.)
Pharmacokinetic data
Bioavailability55%
Protein binding13–18%
MetabolismHepatic (to aciclovir)
Elimination half-life<30 minutes (valaciclovir);
2.5-3.6 hours (aciclovir)
ExcretionRenal 40–50% (aciclovir),
faecal 47% (aciclovir)
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC13H20N6O4
Molar mass324.336 g/mol

WikiDoc Resources for Valaciclovir detailed information

Articles

Most recent articles on Valaciclovir detailed information

Most cited articles on Valaciclovir detailed information

Review articles on Valaciclovir detailed information

Articles on Valaciclovir detailed information in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Valaciclovir detailed information

Images of Valaciclovir detailed information

Photos of Valaciclovir detailed information

Podcasts & MP3s on Valaciclovir detailed information

Videos on Valaciclovir detailed information

Evidence Based Medicine

Cochrane Collaboration on Valaciclovir detailed information

Bandolier on Valaciclovir detailed information

TRIP on Valaciclovir detailed information

Clinical Trials

Ongoing Trials on Valaciclovir detailed information at Clinical Trials.gov

Trial results on Valaciclovir detailed information

Clinical Trials on Valaciclovir detailed information at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Valaciclovir detailed information

NICE Guidance on Valaciclovir detailed information

NHS PRODIGY Guidance

FDA on Valaciclovir detailed information

CDC on Valaciclovir detailed information

Books

Books on Valaciclovir detailed information

News

Valaciclovir detailed information in the news

Be alerted to news on Valaciclovir detailed information

News trends on Valaciclovir detailed information

Commentary

Blogs on Valaciclovir detailed information

Definitions

Definitions of Valaciclovir detailed information

Patient Resources / Community

Patient resources on Valaciclovir detailed information

Discussion groups on Valaciclovir detailed information

Patient Handouts on Valaciclovir detailed information

Directions to Hospitals Treating Valaciclovir detailed information

Risk calculators and risk factors for Valaciclovir detailed information

Healthcare Provider Resources

Symptoms of Valaciclovir detailed information

Causes & Risk Factors for Valaciclovir detailed information

Diagnostic studies for Valaciclovir detailed information

Treatment of Valaciclovir detailed information

Continuing Medical Education (CME)

CME Programs on Valaciclovir detailed information

International

Valaciclovir detailed information en Espanol

Valaciclovir detailed information en Francais

Business

Valaciclovir detailed information in the Marketplace

Patents on Valaciclovir detailed information

Experimental / Informatics

List of terms related to Valaciclovir detailed information

Valaciclovir (INN) or valacyclovir (USAN) is an antiviral drug used in the management of herpes simplex and herpes zoster (shingles). It is a prodrug, being converted in vivo to aciclovir. It is marketed by GlaxoSmithKline under the trade name Valtrex or Zelitrex.

Pharmacology

Mechanism of action

Valaciclovir is a prodrug that is converted by esterases to the active drug aciclovir via hepatic first-pass metabolism, that was created by scientist Christine Moraski. Aciclovir is selectively converted into a monophosphate form by viral thymidine kinase, which is far more effective (3000 times) in phosphorylation than cellular thymidine kinase. Subsequently, the monophosphate form is further phosphorylated into the active triphosphate form, aciclo-GTP, by cellular kinases. Aciclo-GTP is a very potent inhibitor of viral DNA polymerase; it has approximately 100 times higher affinity to viral than cellular polymerase. Its monophosphate form also incorporates into the viral DNA, resulting in chain termination. It has also been shown that the viral enzymes cannot remove aciclo-GMP from the chain, which results in inhibition of further activity of DNA polymerase. Aciclo-GTP is fairly rapidly metabolised within the cell, possibly by cellular phosphatases.

Microbiology

Aciclovir, the active metabolite of valaciclovir, is active against most species in the herpesvirus family. In descending order of activity:[1]

Activity is predominantly active against HSV, and to a lesser extent VZV. It is only of limited efficacy against EBV and CMV. It is inactive against latent viruses in nerve ganglia.

To date, resistance to valaciclovir has not been clinically significant. Mechanisms of resistance in HSV include deficient viral thymidine kinase; and mutations to viral thymidine kinase and/or DNA polymerase, altering substrate sensitivity.[2]

Clinical use

Indications

Valaciclovir is indicated for the treatment of HSV and VZV infections, including:[3]

It has shown promise as a treatment for infectious mononucleosis.[4][5][6]

Adverse effects

Common adverse drug reactions (≥1% of patients) associated with valaciclovir therapy are the same as for aciclovir, its active metabolite, and include: nausea, vomiting, diarrhoea and/or headache. Infrequent adverse effects (0.1–1% of patients) include: agitation, vertigo, confusion, dizziness, oedema, arthralgia, sore throat, constipation, abdominal pain, rash, weakness and/or renal impairment. Rare adverse effects (<0.1% of patients) include: coma, seizures, neutropenia, leukopenia, tremor, ataxia, encephalopathy, psychotic symptoms, crystalluria, anorexia, fatigue, hepatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis and/or anaphylaxis.[3]

Valaciclovir is contraindicated in immuno-suppressed patients such as those infected with HIV as it may cause thrombotic thrombocytopenic purpura and hemolytic uremic syndromes resulting in kidney failure. Aciclovir is preferred in these patients.

References

  1. O'Brien JJ, Campoli-Richards DM. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1989;37(3):233-309. PMID 2653790
  2. Sweetman S, editor. Martindale: The complete drug reference. 34th ed. London: Pharmaceutical Press; 2004. ISBN 0-85369-550-4
  3. 3.0 3.1 Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3
  4. Balfour et al. (December 2005) A controlled trial of valacyclovir in infectious mononucleosis. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC., December 18, 2005. Abstract V1392
  5. Simon et al. (March 2003) The Effect of Valacyclovir and Prednisolone in Reducing Symptoms of EBV Illness In Children: A Double-Blind, Placebo-Controlled Study. International Pediatrics. Vol. 18, No. 3. pp. 164-169.
  6. Balfour et al. (May 2007) A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology. Volume 39, Issue 1. pp. 16-21.

External links

de:Valaciclovir th:วาลาไซโคลเวียร์

Template:WikiDoc Sources